Back to search

Switzerland· 53747003

Ultiva 5 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

A remifentanil product, registered in Switzerland by Aspen Pharma Schweiz GmbH and dispensed under Swissmedic category A+. The same ATC class is registered in 18 of our 19 countries.

Cat A+ (Swissmedic)ATC N01AH06

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · CHPublic registernormalisedUltiva 5 mg, Pulver für ein Konzentra…ATCN01AH06REGISTER NO.53747003PACKS LISTED0CHECKEDJune 26, 2026

Where it is registered

Remifentanil is registered in 18 of 19 countries.

Countries holding a registration under ATC N01AH06 (remifentanil), each read from that country’s own register.

  • This record: Switzerland
  • 10 of them publish a price we can compare per daily dose

Remifentanil · ATC N01AH06

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of remifentanil costs, country by country.

Normalised to the WHO defined daily dose (52.5 mcg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Remifentanil · price per daily dose (52.5 mcg)

USD · FX 28 Sept 2026

  • FI Finland$0.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Manufacturer
Aspen Pharma Schweiz GmbH
Country
Switzerland (CH)
ATC code
N01AH06
ATC class
Remifentanil
Defined daily dose
52.5 mcg, P
Swissmedic category
A+
Reimbursed
No
Last checked
June 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

123 interactions on record for remifentanil.

Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Remifentanil · interactions on record

123 records

  • 18 severe
  • 91 moderate
  • 14 info

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f6646d5f-2c79-4673-b1de-6ca701e34131
GET /v1/drugs/f6646d5f-2c79-4673-b1de-6ca701e34131?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "source": "swissmedic_auth",
  "heilmittelcode": "Synthetika"
}

See everything about remifentanil.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.